Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 –…
Tag: pricesensitive
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 –…
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –…
ObsEva Announces Dismissal of Moratorium Proceedings
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 –…
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 –…
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 –…
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 –…
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of…
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of…
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022 –…
